EO-3021 Demonstrates Effectiveness in CLDN18.2-Expressing Cancer Models

Claudin 18.2 (CLDN18.2), a protein overexpressed in several types of cancer including gastric, gastroesophageal junction, and pancreatic cancer, has been the focus of recent research. Elevation Oncology Inc. has presented preclinical data highlighting the efficacy of EO-3021, an antibody-drug conjugate (ADC) designed to target CLDN18.2. The research demonstrated that when EO-3021 is used in combination with VEGFR-2 or PD-1 inhibitors, it shows promising results in models of gastric adenocarcinoma. This development could pave the way for new treatment options for patients with CLDN18.2-expressing cancers.